Additional Details

  • Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect

    Massachusetts General Hospital
    Boston MA. 02114
    View Details
  • Move With Air: Physiological Response Assessment

    Centre of Innovative Medicine of the McGill University Health Centre
    Montreal QC. H4A 3J1
    View Details
  • Move With Air: Exercise Training Study

    Centre of Innovative Medicine of the McGill University Health Centre
    Montreal QC. H4A 3J1
    View Details
  • An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

    UCLA Health Westwood Medical Plaza
    Westwood CA. 90095
    View Details
  • An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

    Arizona Pulmonary Specialists
    Phoenix AZ. 85012
    View Details
  • An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

    Summit Health
    Bend OR. 97701
    View Details
  • An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

    Vincent Medical Group
    Indianapolis IN. 46260
    View Details
  • Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation

    University of South Florida/ Tampa General Hospital
    Tampa FL. 33606
    View Details
  • Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

    University of Oklahoma Health Sciences Center (OUHSC)
    Oklahoma City OK. 73104-5417
    View Details
  • Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

    Southeastern Research Center
    Winston-Salem NC. 27103-4007
    View Details
  • Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

    Metroplex Pulmonary and Sleep Center
    McKinney TX. 75069-1898
    View Details
  • Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

    Florida Lung Asthma and Sleep Specialist
    Celebration FL. 34747-1818
    View Details
  • Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

    Bogan Sleep Consultants, LLC
    Columbia SC. 29201-2953
    View Details
  • Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

    Univerity of Texas Southwestern Medical Center
    Dallas TX. 75235-6243
    View Details
  • Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

    Keck School of Medicine of USC
    Los Angeles CA. 90033
    View Details
  • Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

    Research Centers of America
    McKinney TX. 75071
    View Details
  • Cough Reduction in IPF With Nalbuphine ER

    The Pacific Lung Health Centre - St. Pauls Hospital
    Vancouver V6Z 1Y6
    View Details
  • Cough Reduction in IPF With Nalbuphine ER

    Dynamic Drug Advancement
    Ajax L1S 2J5
    View Details
  • Cough Reduction in IPF With Nalbuphine ER

    Office of Dr. Syed Anees MD
    Windsor N8X1T3
    View Details
  • Cough Reduction in IPF With Nalbuphine ER

    Centre for Lung Health Clinic
    Vancouver V5Z 1M9
    View Details